Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies

Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug testing on primary CLL cells and identified synerg...

Full description

Bibliographic Details
Main Authors: Katrine Melvold, Mariaserena Giliberto, Linda Karlsen, Pilar Ayuda‐Durán, Robert Hanes, Toril Holien, Jorrit Enserink, Jennifer R. Brown, Geir E. Tjønnfjord, Kjetil Taskén, Sigrid S. Skånland
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:Molecular Oncology
Subjects:
cell signaling
chronic lymphocytic leukemia
drug sensitivity
mantle cell lymphoma
MEK inhibitors
multiple myeloma
Online Access:https://doi.org/10.1002/1878-0261.13153

Internet

https://doi.org/10.1002/1878-0261.13153

Similar Items